ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings for Oct., Nov., Future

September 29, 1989

NIH-funded HapMap consortium publishes first phase of catalog.

October 28, 2005

In Brief: Ross, Harvey To Lead Cancer Center Group; NCI Director In Office By Aug. 1, Varmus Says

May 19, 1995

Groups Warn Against Cuts In Research, Seek Funds For NCI

February 10, 1995

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987

AACI Summarizes Position On New Core Guidelines

May 16, 1980